Cancer Institute And Hospital, Chinese Academy Of Medical Sciences

This trial is testing whether combining chemotherapy with two immunotherapy drugs, given before surgery, can completely eliminate triple-negative breast cancer in people with stage II-III disease. Participants will receive six cycles of the combination, and the main goal is to se…

This study looks at whether a smaller lung surgery after immunotherapy works as well as the standard larger surgery for people with stage II-IIIB non-small cell lung cancer. About 354 patients whose tumors shrank with immunotherapy will choose either a limited or conventional sur…

This phase II trial tests a personalized strategy for people with resectable esophageal squamous cell carcinoma. Participants first receive a combination of chemotherapy and the immunotherapy drug sugemalimab. Those whose tumors shrink significantly then get radiation plus more i…

This early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…

This study tests a shorter, more intense radiation schedule (hypofractionation) given after complete surgical removal of thymic tumors. The goal is to see if it can prevent the cancer from coming back while causing fewer side effects than standard radiation. About 50 adults with …

This early study tests whether combining a drug called lurbinectedin with radiation therapy is safe for people with small cell lung cancer that has one new tumor after initial treatment. The drug works by damaging cancer cell DNA, similar to radiation. The goal is to see if this …

This study tests whether a shorter, more focused radiation treatment (accelerated partial breast irradiation) after breast-conserving surgery can effectively control cancer in the breast and nearby lymph nodes for people with early-stage breast cancer. About 537 participants with…

This study tests a combination of three drugs (orelabrutinib, zuberitamab, and chemotherapy) in 65 adults with untreated marginal zone lymphoma, a slow-growing blood cancer. The goal is to see if the treatment can make all signs of cancer disappear for at least 24 months. Partici…

This phase 2 trial tests a combination of the immunotherapy drug glofitamab plus two chemotherapy drugs (gemcitabine and oxaliplatin) in 40 adults with refractory diffuse large B-cell lymphoma that did not respond to initial treatment. The main goal is to see how many patients ac…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can help people with large, locally advanced non-small cell lung cancer. About 50 participants will receive two cycles of toripalimab plus chemo, followed by chemorad…

This study looks at whether giving extra radiation to lymph nodes behind the breastbone can help prevent breast cancer from returning in high-risk patients. About 2,400 people who had a mastectomy and had cancer in their lymph nodes will take part. The goal is to see if this extr…

This phase II trial is testing whether adding the immunotherapy drug toripalimab to standard chemoradiotherapy can improve outcomes for patients with high-risk locally advanced cervical cancer. About 57 participants will receive the combination, followed by maintenance toripalima…

This phase 2 trial tests a combination of three drugs—selinexor, thalidomide, and dexamethasone—in 40 adults with relapsed or refractory Langerhans cell histiocytosis (LCH), a rare immune cell disorder. The goal is to see if the XTD regimen can shrink tumors and delay disease pro…

This trial is developing a new, non-invasive urine test for bladder cancer. It uses a microfluidic chip to isolate tiny particles called exosomes from urine and analyze their genetic and protein content. The goal is to create a diagnostic model that can detect bladder cancer accu…

This study enrolls 4,000 people with urothelial carcinoma to test whether artificial intelligence can predict HER2 expression using MRI scans and pathology images. The goal is to create a model that accurately assesses HER2 status without needing invasive biopsies, helping doctor…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This observational study follows 138 people who had surgery for esophageal cancer. Researchers use a saliva test called PEPTEST to measure reflux before and after surgery. The goal is to understand how often reflux happens and what factors, like surgical technique or lifestyle, m…

This study looks at whether tracking tiny bits of tumor DNA in the blood (ctDNA) can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment. The goal is to see if changes in ctDNA levels matc…

This study looks back at 300 people with advanced stomach or gastroesophageal junction cancer to see how different treatments before and after surgery affect survival. The goal is to find out which treatment plans work best and whether tumor shrinkage after pre-surgery therapy pr…

This study looks back at medical records of 10,000 people with non-small cell lung cancer who received immunotherapy before surgery. Researchers want to find out which follow-up treatments after surgery help patients live longer and reduce the chance of cancer coming back. The go…